David A Barriere Selected Research

Channelopathies

12/2021

The Class I HDAC Inhibitor, MS-275, Prevents Oxaliplatin-Induced Chronic Neuropathy and Potentiates Its Antiproliferative Activity in Mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David A Barriere Research Topics

Disease

2	Neoplasms (Cancer) 12/2021 - 01/2018
2	Colorectal Neoplasms (Colorectal Cancer) 12/2021 - 01/2018
1	Arthralgia (Joint Pain) 10/2022
1	Osteoarthritis 10/2022
1	Pain (Aches) 10/2022
1	Chronic Pain 10/2022
1	Rheumatic Diseases (Rheumatism) 10/2022
1	Peripheral Nervous System Diseases (PNS Diseases) 12/2021
1	Hypersensitivity (Allergy) 12/2021
1	Channelopathies 12/2021
1	Cold Hypersensitivity 01/2018
1	Polyps 01/2018

Drug/Important Bio-Agent (IBA)

2	Oxaliplatin (Eloxatin)FDA LinkGeneric 12/2021 - 01/2018
1	Acid Sensing Ion ChannelsIBA 10/2022
1	Lysophosphatidylcholines (Lysophosphatidylcholine)IBA 10/2022
1	entinostat (MS 275)IBA 12/2021
1	Histone Deacetylases (Histone Deacetylase)IBA 12/2021
1	Ion Channels (Ion Channel)IBA 12/2021
1	Potassium Channels (Potassium Channel)IBA 12/2021
1	Histone Deacetylase InhibitorsIBA 12/2021
1	Riluzole FDA LinkGeneric 01/2018
1	potassium channel protein TREK-1IBA 01/2018

Therapy/Procedure

1	Intra-Articular Injections 10/2022
1	Pain Management 10/2022